Evidence map›Paper›PMID 31761958›Full record

Trial reportGeroScience2019

Topical rapamycin reduces markers of senescence and aging in human skin: an exploratory, prospective, randomized trial.

Christina Lee Chung, Ibiyonu Lawrence, Melissa Hoffman, Dareen Elgindi, Kumar Nadhan, Manali Potnis, Annie Jin, Catlin Sershon, Rhonda Binnebose, Antonello Lorenzini and 1 more

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in GeroScience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 117 papers.

0numbers the graph read from it
0cells of the map it votes in
117citing papers in PubMed
15.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

117 citing papers in PubMed, 195 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Molecular Targets in Modern Cosmetic Science.Molecules (Basel, Switzerland) · 2026
    Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

57 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Christina Lee ChungDepartment of Dermatology, Drexel University College of Medicine, Philadelphia, PA, USA.
Ibiyonu LawrenceDepartment of Medicine, Drexel University College of Medicine, Philadelphia, PA, USA.
Melissa HoffmanDepartment of Dermatology, Drexel University College of Medicine, Philadelphia, PA, USA.
Dareen ElgindiDepartment of Dermatology, Drexel University College of Medicine, Philadelphia, PA, USA.
Kumar NadhanDepartment of Dermatology, Drexel University College of Medicine, Philadelphia, PA, USA.
Manali PotnisDepartment of Pathology and Laboratory Medicine, Drexel University College of Medicine, 245 N 15th Street, Philadelphia, PA, 19102, USA.
Annie JinDepartment of Dermatology, Drexel University College of Medicine, Philadelphia, PA, USA.
Catlin SershonDepartment of Dermatology, Drexel University College of Medicine, Philadelphia, PA, USA.
Rhonda BinneboseDepartment of Pathology and Laboratory Medicine, Drexel University College of Medicine, 245 N 15th Street, Philadelphia, PA, 19102, USA.
Antonello LorenziniDepartment of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
Christian SellDepartment of Pathology and Laboratory Medicine, Drexel University College of Medicine, 245 N 15th Street, Philadelphia, PA, 19102, USA. cs389@drexel.edu.ORCID http://orcid.org/0000-0002-4332-1141
Drexel University · USUniversity of Bologna · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aging is a major risk factor for the majority of human diseases, and the development of interventions to reduce the intrinsic rate of aging is expected to reduce the risk for age-related diseases including cardiovascular disease, cancer, and dementia. In the skin, aging manifests itself in photodamage and dermal atrophy, with underlying tissue reduction and impaired barrier function. To determine whether rapamycin, an FDA-approved drug targeting the mechanistic target of rapamycin (mTOR) complex, can reduce senescence and markers of aging in human skin, an exploratory, placebo-controlled, interventional trial was conducted in a clinical dermatology setting. Participants were greater than 40 years of age with evidence of age-related photoaging and dermal volume loss and no major morbidities. Thirty-six participants were enrolled in the study, and nineteen discontinued or were lost to follow-up. A significant (P = 0.008) reduction in p16

Indexed as

Administration, TopicalAdultBiopsyCellular SenescenceCollagen Type VIICyclin-Dependent Kinase Inhibitor p16FemaleHumansImmunohistochemistryImmunosuppressive AgentsMaleMiddle AgedProspective StudiesSirolimusSkinSkin AgingCollagen Type VIICyclin-Dependent Kinase Inhibitor p16Immunosuppressive AgentsSirolimusagingkeratosesmTORphotoagingrapamycinsenescence

Identifiers

PMID31761958
PMCPMC6925069
OpenAlexW2989720469

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.